<DOC>
	<DOCNO>NCT01501799</DOCNO>
	<brief_summary>EPIDUO™ ( adapalene benzoyl peroxide ) Gel 0.1 % /2.5 % , market GALDERMA LABORATORIES , L.P. , safe effective topical therapy use treatment acne vulgaris . Actavis Mid-Atlantic LLC develop generic formulation adapalene benzoyl peroxide topical gel 0.1 % /2.5 % , current study design evaluate safety efficacy formulation determine bioequivalent EPIDUO™ .</brief_summary>
	<brief_title>A Bioequivalence Study With Clinical Endpoints Comparing Adapalene Benzoyl Peroxide Topical Gel 0.1 % /2.5 % ( Actavis Mid-Atlantic LLC ) To Epiduo™ ( Adapalene Benzoyl Peroxide ) Gel 0.1 % /2.5 % ( Galderma Laboratories , L.P. ) Treatment Mild Severe Acne Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Adapalene , Benzoyl Peroxide Drug Combination</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>1 . Male nonpregnant female patient must age 12 40 year old inclusive . 2 . Patients 18 year age old must provide IEC/IRB approve write informed consent . Patients age 12 17 year age must provide IEC/IRB approve write assent ; write assent must accompany IEC/IRB approve write informed consent patient 's legally acceptable representative ( i.e. , parent guardian ) . In addition , patient legally acceptable representative ( i.e. , parent guardian ) must sign HIPAA authorization , applicable . 3 . Patients must definite clinical diagnosis mild severe acne vulgaris ( Grade 2 , Grade 3 Grade 4 IGE ) . 4 . Patients must minimum 20 inflammatory lesion maximum 100 minimum 25 maximum 100 noninflammatory lesion ( i.e. , open close comedo ) 2 nodulocystic lesion ( i.e. , nodule cyst ) baseline . For purpose study treatment evaluation , lesion limit facial treatment area . Lesions involve eye , angle nose ( i.e. , line around nostril nostril ) scalp exclude count . Patients may acne lesion area body ( e.g. , back ) . 5 . Female patient childbearing potential must use accepted method birth control must agree continue practice abstinence , 30 day prior study entry 30 day last administration study drug . All female patient consider childbearing potential unless surgically sterilize postmenopausal least 1 year . Abstinence acceptable method birth control . Any following method birth control acceptable : oral contraceptive , contraceptive patches/implants ( e.g. , Norplant® ) DepoProvera® , double barrier method ( e.g. , condom spermicide ) IUD . Female patient must negative urine pregnancy test baseline . A negative result pregnancy test minimum sensitivity least 50 mIU/ml hCG obtain . 6 . All male patient must agree use accept method birth control partner , day first dose administration 30 day last administration study drug . Abstinence acceptable method birth control . Any following method birth control acceptable : oral contraceptive , contraceptive patches/implants ( e.g. , Norplant® ) , DepoProvera® , double barrier method ( e.g. , condom spermicide ) IUD . 7 . Patients must willing able understand comply requirement protocol , include attendance require study visit . 8 . Patients must willing refrain use treatment acne vulgaris , include antibiotic , investigational product , acne present face . Patients may use topical acne treatment significant measurable systemic absorption treatment acne back , shoulder chest ( e.g. , benzoyl peroxide , salicylic acid ) . 9 . Patients must good health free clinically significant disease . 10 . Patients use makeup must use brands/types makeup minimum period 14 day prior study entry must agree change makeup brand/type frequency use throughout study . 1 . Female patient pregnant , nurse plan become pregnant study participation ( Visit 1 Visit 5 ) exclude study participation . 2 . Patients know hypersensitivity benzoyl peroxide , adapalene , retinoids , excipients exclude study participation . 3 . Patients condition may interfere evaluation acne vulgaris . Such condition include , limited follow lesion face : rosacea ; seborrheic dermatitis ; perioral dermatitis ; corticosteroidinduced acne folliculitis ; carcinoid syndrome ; squamous cell carcinoma ; mastocytosis ; acneiform eruption cause makeup medication ; bacterial folliculitis ; facial psoriasis ; facial eczema . 4 . Patients acne congoblata , acne fulminans , secondary acne ( e.g. , chloracne drug induce acne ) exclude participation . 5 . Patients treat systemic antibiotic systemic antiacne drug systemic antiinflammatory drug within 30 day prior baseline exclude study participation . 6 . Patients treated prescription and/or overthecounter topical medication treatment acne vulgaris include antibiotic , topical corticosteroid , αhydroxy/glycolic acid , benzoyl peroxide , topical antiinflammatory medication face within 14 day prior baseline exclude study participation . 7 . Patients currently take treat systemic corticosteroid ( include intranasal inhaled corticosteroid ) within 30 day prior baseline exclude study participation . 8 . Patients start hormonal therapy change dosage hormonal therapy within 3 month prior baseline exclude study participation . The dosage frequency use hormonal therapy start great 3 month prior baseline must remain unchanged throughout study ( Visit 1 Visit 5 ) . Hormonal treatment include , limited , estrogenic progestational agent birth control pill . 9 . Patients use androgen receptor blocker ( spironolactone flutamide ) exclude study participation . 10 . Patients receive oral retinoids ( e.g. , isotretinoin ) within 180 day prior study entry , use therapeutic vitamin A supplement great 10,000 units/day ( multivitamin allow ) within 180 day prior study entry , apply topical retinoids ( e.g. , tretinoin , tazarotene , adapalene ) face within 2 week prior baseline exclude study participation . 11 . Patients receive radiation therapy and/or antineoplastic agent within 90 day prior baseline exclude study participation . 12 . Patients unstable medical disorder clinically significant lifethreatening disease exclude study participation . 13 . Patients ongoing malignancy require systemic treatment exclude study participation . In addition , patient malignancy skin facial area exclude study participation . 14 . Patients facial hair exclude study participation . Unacceptable facial hair include , limited , beard , long sideburn . A welltrimmed mustache acceptable . Patients perform wax epilation face within 14 day prior baseline also exclude study participation . 15 . Patients engage activity involve excessive prolonged exposure sunlight weather extreme , wind cold , exclude study participation . 16 . Patients consume excessive amount alcohol ( great two drink per day ) use drug abuse ( include , limited , cannabinoids cocaine ) judge history exclude study participation . 17 . Patients participate investigational drug study ( i.e. , patient treat investigational drug ) within 30 day prior baseline exclude study participation . Patients participate nontreatment study observational study registry study consider inclusion . 18 . Patients previously enrol study exclude study participation . 19 . Patients within 30 day prior baseline study cryodestruction chemodestruction , dermabrasion , photodynamic therapy , acne surgery , intralesional steroid , xray therapy exclude study participation . 20 . Patients laser therapy , electrodessication facial area within 180 day prior study entry exclude participation . 21 . Patients cosmetic procedure ( e.g. , facial ) may affect efficacy safety profile investigational product within 14 day prior study entry exclude participation . 22 . Patients general anesthesia reason patient receive neuromuscular block agent within 14 day prior study entry exclude study participation . 23 . Patients baseline local irritation score 3 ( severe , marked/intense ) score use Application Site Reaction Scale ( Section 5.2 ) exclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>acne</keyword>
	<keyword>adapalene/benzoyl peroxide</keyword>
	<keyword>Epiduo</keyword>
	<keyword>Mild severe acne vulgaris</keyword>
</DOC>